Braidwell LP Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Braidwell LP increased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 231.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,225,448 shares of the company's stock after purchasing an additional 855,990 shares during the period. Braidwell LP owned 2.36% of 4D Molecular Therapeutics worth $13,247,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at about $40,000. Values First Advisors Inc. purchased a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $57,000. Quest Partners LLC increased its holdings in 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company's stock worth $121,000 after acquiring an additional 5,745 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after purchasing an additional 3,922 shares during the period. Finally, Proficio Capital Partners LLC purchased a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $108,000. Institutional investors own 99.27% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Leerink Partners reiterated an "outperform" rating and issued a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Thursday, November 14th. Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, September 23rd. Chardan Capital reiterated a "buy" rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Morgan Stanley started coverage on 4D Molecular Therapeutics in a report on Thursday, November 21st. They set an "underweight" rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.13.

4D Molecular Therapeutics Price Performance

FDMT stock traded down $0.03 during midday trading on Friday, hitting $7.84. The stock had a trading volume of 335,675 shares, compared to its average volume of 897,652. The business has a 50-day moving average of $8.83 and a two-hundred day moving average of $15.89. The firm has a market cap of $362.44 million, a price-to-earnings ratio of -2.75 and a beta of 2.82. 4D Molecular Therapeutics, Inc. has a 52-week low of $7.32 and a 52-week high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.